Jenny Barnett
Co-Founder & Chief Executive Officer Monument Therapeutics
Jenny brings a unique blend of commercial and scientific expertise to drive Monument’s mission to transform neuroscience through precision medicine. Previously Chief Scientific Officer at Cambridge Cognition, Jenny played a pivotal role in establishing Monument Tx as a successful spin-out, securing substantial funding to support its innovative solutions.
Jenny holds an MA in Experimental Psychology from Oxford University and a PhD in Schizophrenia Epidemiology from the University of Cambridge, followed by postdoctoral work at Massachusetts General Hospital and the Broad Institute of Harvard and MIT. She has published over 70 papers, holds six patents, and is an honorary member of Cambridge’s Department of Psychiatry.
Seminars
- How multimodal digital biomarkers can sensitively capture early treatment signals and behavioral change before traditional clinical endpoints emerge
- The role of EEG and other neurophysiological readouts in demonstrating target engagement and pharmacodynamic effects during first in human and Phase 1/2 trials
- How structured patient reported outcomes enrich early datasets by capturing subjective symptom shifts that complement objective biomarker trends
- How fluid biomarkers – from inflammatory to neurodegenerative signatures – can provide quantifiable, mechanistic insight into early biological response and disease modulation
- Exploring digital biomarker driven stratification, based on cognitive measures, to move toward biologically homogeneous patient groups and reduce trial heterogeneity
- Investigating a fixed dose combination approach to nicotinic agonism to improve working memory and attentional deficits relevant to a range of neuropsychiatric disorders
- Advancing the first Phase 2 study to target the clinical high risk for psychosis population
- Leveraging the high profile Accelerating Medicines Partnership for Schizophrenia to identify individuals most likely to benefit from early intervention
